CC BY-NC-ND 4.0 · Exp Clin Endocrinol Diabetes 2022; 130(12): 773-782
DOI: 10.1055/a-1932-3136

Selective Inhibition of 11beta-Hydroxysteroiddehydrogenase-1 with BI 187004 in Patients with Type 2 Diabetes and Overweight or Obesity: Safety, Pharmacokinetics, and Pharmacodynamics After Multiple Dosing Over 14 Days

Susanna Bianzano
1   Boehringer Ingelheim International GmbH, Ingelheim, Germany
Cornelia Schepers
2   Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany
Michael Wolff
3   Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany
Tim Heise
4   Profil, Neuss, Germany
Leona Plum-Moerschel
4   Profil, Neuss, Germany
› Author Affiliations


Objective To assess safety, tolerability, pharmacokinetics, and pharmacodynamics of treatment with the selective 11beta-hydroxysteroid dehydrogenase-1 (11beta-HSD1) inhibitor BI 187004 in male and female patients with type 2 diabetes and overweight or obesity.

Methods Randomized, double-blind, parallel-group, placebo-controlled multiple rising dose study, with 10–360 mg BI 187004 once daily over 14 days in 71 patients. Assessments included 11beta-HSD1 inhibition in the liver and subcutaneous adipose tissue ex vivo (clinical trial registry number NCT01874483).

Results BI 187004 was well tolerated and safe in all tested dose groups. The incidence of drug-related adverse events was 51.8% (n=29) for BI 187004 and 35.7% (n=5) for placebo. There were no clinically relevant deviations in laboratory or electrocardiogram parameters besides one patient on 360 mg discontinuing treatment due to moderate supraventricular tachycardia.

BI 187004 was rapidly absorbed within 2 h; exposure increased non-proportionally. The oral clearance was low, apparent volume of distribution was moderate to large, and terminal half-life with 106–124 h was rather long. Urinary tetrahydrocortisol/tetrahydrocortisone ratio decreased, indicating liver 11beta-HSD1 inhibition. Median inhibition of 11beta-HSD1 in subcutaneous adipose tissue biopsies was 87.9–99.4% immediately after the second dose and 73.8–97.5% 24 h after the last dose of BI 187004.

Conclusions BI 187004 was safe and well tolerated over 14 days and could be dosed once daily. Targeted 11beta-HSD1 enzyme inhibition of≥80% could be shown for BI 187004 doses≥40 mg. This dose should be targeted in further studies to test blood glucose lowering in patients with type 2 diabetes and overweight or obesity.

Supplementary Material

Publication History

Received: 18 February 2022
Received: 30 May 2022

Accepted: 20 June 2022

Article published online:
07 November 2022

© 2022. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

  • References

  • 1 Anagnostis P, Athyros VG, Tziomalos K. et al. Clinical review: The pathogenetic role of cortisol in the metabolic syndrome: A hypothesis. J Clin Endocrinol Metab 2009; 94: 2692-2701
  • 2 Morton NM. Obesity and corticosteroids: 11beta-hydroxysteroid type 1 as a cause and therapeutic target in metabolic disease. Mol Cell Endocrinol 2010; 316: 154-164
  • 3 Tomlinson JW, Stewart PM. Cortisol metabolism and the role of 11beta-hydroxysteroid dehydrogenase. Best Pract Res Clin Endocrinol Metab 2001; 15: 61-78
  • 4 Sjostrand M, Jansson PA, Palming J. et al. Repeated measurements of 11beta-HSD-1 activity in subcutaneous adipose tissue from lean, abdominally obese, and type 2 diabetes subjects – no change following a mixed meal. Horm Metab Res 2010; 42: 798-802
  • 5 Paulsen SK, Pedersen SB, Fisker S. et al. 11Beta-HSD type 1 expression in human adipose tissue: Impact of gender, obesity, and fat localization. Obesity (Silver Spring) 2007; 15: 1954-1960
  • 6 Shao S, Zhang X, Zhang M. Inhibition of 11beta-hydroxysteroid dehydrogenase type 1 ameliorates obesity-related insulin resistance. Biochem Bioph Res Co 2016; 478: 474-480
  • 7 Stimson RH, Andersson J, Andrew R. et al. Cortisol release from adipose tissue by 11β-hydroxysteroid dehydrogenase type 1 in humans. Diabetes 2009; 58: 46-53
  • 8 Stimson RH, Andrew R, McAvoy NC. et al. Increased whole-body and sustained liver cortisol regeneration by 11beta-hydroxysteroid dehydrogenase type 1 in obese men with type 2 diabetes provides a target for enzyme inhibition. Diabetes 2011; 60: 720-725
  • 9 Rask E, Olsson T, Soderberg S. et al. Tissue-specific dysregulation of cortisol metabolism in human obesity. J Clin Endocrinol Metab 2001; 86: 1418-1421
  • 10 Stewart PM, Tomlinson JW. Selective inhibitors of 11beta-hydroxysteroid dehydrogenase type 1 for patients with metabolic syndrome: Is the target liver, fat, or both?. Diabetes 2009; 58: 14-15
  • 11 Rosenstock J, Banarer S, Fonseca VA. et al. The 11b-hydroxysteroid dehydrogenase type 1 inhibitor INCB13739 improves hyperglycemia in patients with type 2 diabetes inadequately controlled by metformin monotherapy. Diabetes Care 2010; 33: 1516-1522
  • 12 Bianzano S, Heise T, Jungnik A. et al. Safety, tolerability, pharmacokinetics and pharmacodynamics of single oral doses of BI 187004, an inhibitor of 11beta-hydroxysteroid dehydrogenase-1, in healthy male volunteers with overweight or obesity. Clin Diabetes Endocrinol 2021; 7: 16
  • 13 Heise T, Graefe-Mody EU, Hüttner S. et al. Pharmacokinetics, pharmacodynamics and tolerability of multiple oral doses of linagliptin, a dipeptidyl peptidase-4 inhibitor in male type 2 diabetes patients. Diabetes Obes. Metabolism 2009; 11: 786-794
  • 14 Freude S, Heise T, Worle HJ. et al. Safety, pharmacokinetics and pharmacodynamics of BI 135585, a selective 11beta-HSD1 inhibitor in humans: Liver and adipose tissue 11beta-HSD1 inhibition after acute and multiple administrations over 2 weeks. Diabetes Obes Metab 2016; 18: 483-490
  • 15 Stomby A, Andrew R, Walker BR. et al. Tissue-specific dysregulation of cortisol regeneration by 11betaHSD1 in obesity: Has it promised too much?. Diabetologia 2014; 57: 1100-1110
  • 16 Semjonous NM, Sherlock M, Jeyasuria P. et al. Hexose-6-phosphate dehydrogenase contributes to skeletal muscle homeostasis independent of 11beta-hydroxysteroid dehydrogenase type 1. Endocrinology 2011; 152: 93-102
  • 17 Lavery GG, Zielinska AE, Gathercole LL. et al. Lack of significant metabolic abnormalities in mice with liver-specific disruption of 11beta-hydroxysteroid dehydrogenase type 1. Endocrinology 2012; 153: 3236-3248
  • 18 Palermo M, Shackleton CH, Mantero F. et al. Urinary free cortisone and the assessment of 11 beta-hydroxysteroid dehydrogenase activity in man. Clin Endocrinol (Oxf) 1996; 45: 605-611
  • 19 Heise T, Morrow L, Hompesch M. et al. Safety, efficacy and weight effect of two 11beta-HSD1 inhibitors in metformin-treated patients with type 2 diabetes. Diabetes Obes Metab 2014; 16: 1070-1077
  • 20 Sjöstrand M, Hansson GI, Hartford M. et al. Pharmacodynamic effects of AZD4017, a selective 11beta-HSD1 inhibitor, in liver and adipose tissue. Diabetes 2011; 60 A319-Abstract 1161-P
  • 21 Courtney R, Stewart PM, Toh M. et al. Modulation of 11beta-hydroxysteroid dehydrogenase (11betaHSD) activity biomarkers and pharmacokinetics of PF-00915275, a selective 11betaHSD1 inhibitor. J Clin Endocrinol Metab 2008; 93: 550-556
  • 22 Williams WV, Huber R, Levy R. et al. Endocrine homeostasis with inhibition of tissue-specific cortisone reductase activity in healthy volunteers and obese insulin resistant subjects following oral INCB13739 11beta-HSD1 inhibitor therapy. Diabetes 2007; 56: A2255
  • 23 Gibbs JP, Emery MG, McCaffery I. et al. Population pharmacokinetic/pharmacodynamic model of subcutaneous adipose 11beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1) activity after oral administration of AMG 221, a selective 11beta-HSD1 inhibitor. J Clin Pharmacol 2011; 51: 830-841
  • 24 Hamilton BS, Himmelsbach F, Nar H. et al. Pharmacological characterization of the selective 11beta-hydroxysteroid dehydrogenase 1 inhibitor, BI 135585, a clinical candidate for the treatment of type 2 diabetes. Eur J Pharmacol 2015; 746: 50-55